A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2001
11/27/2001	US6323220 Substituted pyridine or piperidine compounds
11/27/2001	US6323218 Treatment of alzheimer*s disease with metal chelates for amyloidosis
11/27/2001	US6323216 Selective antagonists of the 5-ht.sub.3 serotonin-like receptor and can therefore be used, as anti-emetics as well as in various pathological conditions of the central nervous system, and as antitussives.
11/27/2001	US6323214 Allosteric adenosine receptor modulators
11/27/2001	US6323208 Compounds to treat neurodegenerative, psychotropic drug and alcohol induced central and induced central and peripheral nervous system disorders.
11/27/2001	US6323206 Antiinflammatory agents and viricides for aids with cytokinesand chemokines
11/27/2001	US6323204 Analgesics, antiinflammatory agents and antiischemic agents
11/27/2001	US6323199 Aromatic heterocyclic hydroxy amines or amides for treatment of inflammation
11/27/2001	US6323198 Cognition activators for gamma-aminobutyric acid binding receptors
11/27/2001	US6323197 Non-competitive inhibiting of the ampa receptors, these compounds can be used as medicaments for treatment of the central nervous system
11/27/2001	US6323196 Galanthamine derivatives as acetylcholinesterase inhibitors
11/27/2001	US6323195 Enzyme inhibitors and cognition activators
11/27/2001	US6323194 Muscarinic agonists and antagonists
11/27/2001	US6323029 Therapeutic, diagnostic, and research applications for the modulation of glycogen synthase kinase 3 beta expression
11/27/2001	US6322999 Cloned genes coding for human receptors, and cell lines expressing genes, in order to generate a proper screen for human therapeutic compounds
11/27/2001	US6322824 Use of hyperforin and hyperforin-containing extracts in the treatment of dementia diseases
11/27/2001	US6322819 Amphetamine salt covered with enteric release coating
11/27/2001	US6322806 Over-coated chewing gum formulations including tableted center
11/26/2001	CA2322554A1 Cell culture and method for production
11/25/2001	CA2309518A1 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
11/25/2001	CA2309424A1 Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
11/25/2001	CA2309417A1 Apoptotic entities for use in treatment of endothelium dysfunction disorders
11/22/2001	WO2001088148A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
11/22/2001	WO2001088134A2 Novel human lipocalin homologs and polynucleotides encoding the same
11/22/2001	WO2001088132A2 Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods
11/22/2001	WO2001088126A2 REGULATION OF HUMAN α1Α ADRENERGIC RECEPTOR-LIKE G PROTEIN-COUPLED RECEPTOR
11/22/2001	WO2001088125A1 MUTATION IN THE β2 NICOTINIC ACETYLCHOLINE RECEPTOR SUBUNIT ASSOCIATED WITH NOCTURNAL FRONTAL LOBE EPILEPSY
11/22/2001	WO2001088123A1 Ligands specific for an isoform of the prion protein
11/22/2001	WO2001088119A1 Novel g protein-coupled receptor protein and dna thereof
11/22/2001	WO2001088108A1 Neuronal serine-threonine protein kinase
11/22/2001	WO2001088104A2 Neural progenitor cell populations
11/22/2001	WO2001088100A1 Novel method of inducing the differentiation of embryonic stem cells into ectodermal cells and use thereof
11/22/2001	WO2001087980A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
11/22/2001	WO2001087913A2 Method for treating retinal degeneration with purinergic receptor agonists
11/22/2001	WO2001087892A1 Crf receptor antagonists
11/22/2001	WO2001087889A1 Crf receptor antagonists and methods relating thereto
11/22/2001	WO2001087887A2 Neuroprotective and anti-proliferative compounds
11/22/2001	WO2001087886A1 Crf receptor antagonists and methods relating thereto
11/22/2001	WO2001087884A2 Polyketide derivatives
11/22/2001	WO2001087881A1 Piperidyindoles as serotonin receptor ligands
11/22/2001	WO2001087870A1 Hydroxamic acid derivatives
11/22/2001	WO2001087866A1 Cyclohexyl derivatives and their use as therapeutic agents
11/22/2001	WO2001087849A2 Modulators of tnf- alpha signaling
11/22/2001	WO2001087844A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
11/22/2001	WO2001087841A1 Novel polymorph v of torasemide
11/22/2001	WO2001087839A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
11/22/2001	WO2001087838A1 Cyclohexane derivatives and their use as therapeutic agents
11/22/2001	WO2001087830A2 Substituted thioacetamides
11/22/2001	WO2001087343A2 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
11/22/2001	WO2001087338A1 Immunomodulatory human mhc class ii antigen-binding polypeptides
11/22/2001	WO2001087337A1 Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
11/22/2001	WO2001087330A2 Compositions and methods for achieving immune suppression
11/22/2001	WO2001087328A2 Interleukin-1 inhibitors in the treatment of diseases
11/22/2001	WO2001087320A1 Use of piper methysticum or piper wichmannii extracts for treating alcohol dependence
11/22/2001	WO2001087299A1 Aralkyl ester soft drugs
11/22/2001	WO2001087293A1 -secretase inhibitors
11/22/2001	WO2001087291A1 Compositions normalizing circadian rhythm
11/22/2001	WO2001087286A2 Antisense enzyme inhibitors for improving pharmacokinetics of a drug
11/22/2001	WO2001087284A2 Aldosterone antagonist composition for release during aldosterone acrophase
11/22/2001	WO2001087281A2 Method for enhancing cognitive function
11/22/2001	WO2001087280A2 Means for treating attacks of auto-immune diseases
11/22/2001	WO2001087276A1 Hydrogel composition for transdermal drug delivery
11/22/2001	WO2001087267A1 Protein matrix materials, devices and methods of making and using thereof
11/22/2001	WO2001087231A2 Methods and compositions for the diagnosis of schizophrenia
11/22/2001	WO2001046128A3 Tryptase inhibitors
11/22/2001	WO2001042246A3 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
11/22/2001	WO2001034805A3 Human vanilloid receptor gene
11/22/2001	WO2001030969A8 Stanniocalcin proteins and nucleic acids and methods based thereon
11/22/2001	WO2001028578A3 A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME
11/22/2001	WO2001027268A3 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
11/22/2001	WO2001025239A3 Oxazinoquinolones useful for the treatment of viral infections
11/22/2001	WO2001018169A3 Agents and compositions and methods for diagnostic and/or treating or preventing plaque forming diseases
11/22/2001	WO2001014564A3 Polynucleotides expressed in activated t-lymphocytes and proteins encoded thereby
11/22/2001	US20010044937 Transgenic intracytoplasmic sperm injection, retroviral gene transfer, intracytoplasmic nuclear injection, and pronuclear injection; useful as models for human disease/diagnosis, assessing safety and efficiency of drug and gene therapy
11/22/2001	US20010044538 Mitogen-activated protein (MAP) kinase; treating inflammatory diseases; compounds such as 3-(4-fluorophenyl)-1-hydroxy-2-(pyridin-4-yl)-1H-pyrrolo(3,2-b)pyridine
11/22/2001	US20010044535 Heterocyclic compounds containing a guanidine mimic, for inhibition of cell adhesion, treatment of angiogenesis disorders, inflammation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration
11/22/2001	US20010044474 Hydrogel-driven layered drug dosage form
11/22/2001	US20010044471 Hydrogenation of racemic 6-alkoxy-1H-indene-1,2(3H)-dione-2-oxime, with chiral acid, resolution, alkylation, bromination, carboxamidation
11/22/2001	US20010044460 Ophthalmic compositions for treating ocular hypertension
11/22/2001	US20010044459 Hydroxamic acid derivatives
11/22/2001	US20010044452 Anticonvulsants
11/22/2001	US20010044450 5-HT3 receptor antagonists such as alosetron to treat nonconstipated female irritable bowel syndrome
11/22/2001	US20010044448 Prevention/treatment of motor neuron diseases; amyotrophic lateral sclerosis
11/22/2001	US20010044436 Bicyclic inhibitors of glycogen synthase kinase 3
11/22/2001	US20010044428 Aminopyridines and methods of using thereof
11/22/2001	US20010044426 Cyclobutaindolecarboxamide compounds
11/22/2001	US20010044144 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor
11/22/2001	US20010044122 Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
11/22/2001	US20010043945 In admixture with erodible matrix, for reliable controlled release of phenytoin sodium even after storage
11/22/2001	US20010043930 Method for treating cervical dystonia with botulinum toxin type B
11/22/2001	US20010043915 Method for administering a cytokine to the central nervous system and the lymphatic system
11/22/2001	DE10023484A1 New 2-((cycloalkyl- or heterocyclyl-alkyl)-amino)-benzamide derivatives, are VEGF receptor, KDR kinase and FLT kinase inhibitors useful e.g. for treating tumors, psoriasis, arthritis or renal or ophthalmological diseases
11/22/2001	DE10020667A1 Neue Benzoxazin- und Benzothiazin-Derivate und deren Verwendung in Arzneimitteln New benzoxazine and benzothiazine derivatives and their use in medicaments
11/22/2001	DE10009119A1 Vertebraten Globin Vertebrate globin
11/22/2001	CA2781858A1 Modulators of tnf-.alpha. signaling
11/22/2001	CA2410091A1 Piperidyindoles as serotonin receptor ligands
11/22/2001	CA2410077A1 Cyclohexyl derivatives and their use as therapeutic agents
11/22/2001	CA2410028A1 Ligands specific for an isoform of the prion protein
11/22/2001	CA2409703A1 Novel differentiation inducing process of embryonic stem cell to ectodermal cell and its use
11/22/2001	CA2409699A1 Novel polymorph v of torasemide

1 ... 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 ... 1833